Altre lingue Apellis Pharmaceuticals, Inc.

Azioni

APLS

US03753U1060

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 18/04/2024			Variaz. 5gg	Var. 1 gen.
47,51 ^USD	-1,08%		-14,75%	-20,63%

17/04	APELLIS PHARMACEUTICALS, INC. : rating Neutral da Wedbush	ZM
09/04	L'insider di Apellis Pharmaceuticals ha venduto azioni per un valore di 3.743.605 dollari, secondo un recente deposito SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	09/04
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	01/04
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	21/03
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing	20/03
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing	14/03
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing	11/03
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor	11/03
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor	11/03
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024	11/03
Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	07/03
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/03
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing	05/03
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	04/03
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases	27/02
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q4 Revenue $146.4M	27/02
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	27/02
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	27/02
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Apellis Pharmaceuticals, Inc.

Azioni

APLS

US03753U1060

Altre lingue

Filtri